SCHEDULE 13G/A: Cadrenal Therapeutics: Czech Entities Disclose Passive Stake Below 5% Threshold

Three Czech Republic-based entities, Havlickova 648 a.s., Dubnica Property s.r.o., and Miroslav Dornak, have filed an amended Schedule 13G disclosing a collective beneficial ownership of 4.39% in Cadrenal Therapeutics, Inc.

Summary

• Havlickova 648 a.s., Dubnica Property s.r.o., and Miroslav Dornak (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
• The Reporting Persons collectively beneficially own 78,291 shares of Cadrenal Therapeutics, Inc. Common Stock.
• This ownership represents 4.39% of the Issuer's outstanding common stock.
• The percentage is calculated based on 1,782,486 shares of Cadrenal Therapeutics, Inc. outstanding as of December 18, 2024.
• Havlickova 648 a.s. directly holds the 78,291 shares.
• Dubnica Property s.r.o., as the direct parent of Havlickova 648 a.s., controls the voting and dispositive power over these shares.
• Miroslav Dornak also controls the voting and dispositive power over the 78,291 shares held by Havlickova 648 a.s.
• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Cadrenal Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing disclosing beneficial ownership, providing factual information without indicating positive or negative sentiment regarding the company's performance or outlook.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership structure and significant passive holders, confirming that the reported stake is below the 5% threshold for active influence.

Key Dates

Keywords

Cadrenal Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Ownership Disclosure, SEC Filing, Institutional Ownership